

Not an actual patient.

*I'm on a
Mission for
more life
without disease progression*

If your **follicular lymphoma (FL)** has returned or progressed, learn how MONJUVI can help.

What is MONJUVI?

MONJUVI (tafasitamab-cxix) is a prescription medicine given in combination with lenalidomide and rituximab to treat adults with follicular lymphoma (FL) that has come back or that did not respond to previous treatment.

MONJUVI should not be used and is not recommended outside of clinical trials to treat people with a certain type of lymphoma, called marginal zone lymphoma, that has come back or that did not respond to previous treatment.

It is not known if MONJUVI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of MONJUVI?

MONJUVI (tafasitamab-cxix) may cause serious side effects, including:

- **Infusion reactions.** Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI.
- **Low blood cell counts** (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or any bruising or bleeding.
- **Infections.** Serious infections, including infections that can cause death, have happened in people during treatment with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or develop any signs or symptoms of an infection.

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

Achieving remission is possible with MONJUVI


Follicular lymphoma (FL) is a type of cancer that affects the lymph nodes, bone marrow, and other organs, and tends to grow more slowly than other cancers.

Relapse is a common part of the FL journey, and while it may feel discouraging, it's important to remember that remission may still be within reach. That's why working closely with your doctor to choose the next treatment that's right for you is so important. **MONJUVI in combination with rituximab and lenalidomide offers an option that may help you achieve remission.**

How does MONJUVI work?

MONJUVI is not chemotherapy. MONJUVI is a targeted immunotherapy that works with your immune system to help find and kill cancer cells.

B cells are part of a person's immune system. They help your body fight infection. In FL, B cells grow out of control, both in size and number. **MONJUVI targets cancerous B cells directly and activates your immune system to fight FL.** MONJUVI can also affect healthy B cells. The image below illustrates how MONJUVI works.



1 Cancerous B cell with CD19 markers.

2 MONJUVI locates and binds to the CD19 marker on the surface of cancerous B cells.

3 This binding action triggers immune cells to kill the cancer cells.

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

A chance to live longer without disease progression


MONJUVI was studied in 548 adults whose FL returned, got worse, or didn't respond to treatment. There were 2 different treatment groups in the study, and both groups received treatment for up to 12 months.

- Group 1: 273 people received MONJUVI in combination with rituximab and lenalidomide
- Group 2: 275 people received placebo in combination with rituximab and lenalidomide

A placebo is a substance with no active ingredient. How your condition progresses and how you may respond to MONJUVI depends on your individual circumstances.

Median Progression-Free Survival


Median progression-free survival is the length of time after the start of study treatment in which half of the people in a treatment group were alive without their disease getting worse (disease progression).



After a 14.1-month median follow-up in the clinical study, MONJUVI + rituximab and lenalidomide **lowered the risk of disease progression or death by 57%** compared to placebo + rituximab and lenalidomide.


Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

A chance to reach remission



Time to next treatment

In the clinical study, time to next treatment was defined as the time from the start of study treatment to the start of a different, or “next,” treatment for FL for any reason.



During the study, the decision to start a person on a next treatment was based on their doctor’s clinical judgment. The data shown above are not conclusive and should be interpreted with caution. Talk to your doctor if you have any questions.

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.



I'm on a

Mission to reach remission

Get more information, valuable resources, and guidance at [MONJUVI.com/FL](https://www.monjuvi.com/FL)



Not an actual patient or caregiver.

IMPORTANT SAFETY INFORMATION

What are the possible side effects of MONJUVI?

MONJUVI (tafasitamab-cxix) may cause serious side effects, including:

- **Infusion reactions.** Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI.
- **Low blood cell counts** (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or any bruising or bleeding.
- **Infections.** Serious infections, including infections that can cause death, have happened in people during treatment with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or develop any signs or symptoms of an infection.

The most common side effects of MONJUVI when given with lenalidomide and rituximab in people with FL include:

- respiratory tract infections
- diarrhea
- rash
- feeling tired or weak
- muscle and bone pain
- constipation
- cough

These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Incyte Medical Information at [1-855-463-3463](tel:1-855-463-3463).

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use



Not an actual patient.

IMPORTANT SAFETY INFORMATION

Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you

- Have an active infection or have had one recently
- Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby.
 - You should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of MONJUVI
 - Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI
- Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breast milk. Do not breastfeed during treatment and for at least 3 months after your last dose of MONJUVI.

You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation.

Tell your healthcare provider about all the medications you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

1-2-3 get started with MONJUVI

1



Learn how MONJUVI may be right for you

Understanding how a medicine works is only one part of choosing a treatment. Your comfort level with the treatment process and your future care is essential to discuss with your healthcare team as you talk about your next step.

2



Receive MONJUVI in a clinic nearby

MONJUVI is given to you by your healthcare provider as an intravenous (IV) infusion into one of your veins. You can receive MONJUVI in a local clinic or infusion center, so there's no need to travel to a special cancer center, and you can begin treatment as soon as you're ready.

Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions.


If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions.

3



Understand your MONJUVI treatment schedule

MONJUVI is given for up to 12 cycles. Each treatment cycle of MONJUVI lasts for 28 days. Lenalidomide and rituximab are given throughout treatment with MONJUVI.



Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects. Your healthcare provider will decide how many treatments you need.

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What can I expect from treatment?



MONJUVI is given in combination with rituximab and lenalidomide

You will receive MONJUVI as an IV infusion once every week during cycles 1 to 3, and once every 2 weeks during cycles 4 to 12.

Your doctor will give you rituximab as an IV infusion during cycles 1 to 5. You will also take lenalidomide orally once a day on days 1 to 21 of each treatment cycle, for up to 12 cycles.

Rituximab and lenalidomide are medicines that help the immune system respond to cancer. MONJUVI, rituximab, and lenalidomide together may help treat FL. **MONJUVI is not chemotherapy.**



Infusions are typically under 2 hours

Be prepared for your first MONJUVI infusion to take between 1 ½ and 2 ½ hours. The time can vary if your healthcare team needs to make adjustments during treatment. Nurses and other healthcare professionals will be available to help you during your treatment.

After your initial infusion, all subsequent MONJUVI infusions will typically take between 1 ½ and 2 hours.



Infusion reactions are more common at the start of treatment

Infusion reactions can occur at any time during treatment but are more frequent at the beginning. Your healthcare team may delay or completely stop your infusion and may also give you other medicines if you have severe side effects.



Medicine can help prevent infusion reactions

Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions.

If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions.

I'm on a
**Mission for
more family time**



Not an actual patient.

Discussing your next step with your doctor

Educating yourself about MONJUVI and thinking through your priorities ahead of time can help you feel more prepared for discussions with your healthcare team. Here are a few key questions to help you during this important process.



Medical Considerations

- Can I stay with my current healthcare team?
- Is treatment given on an outpatient basis or will I be admitted to a hospital?
- How is this treatment different from what I've tried before?
- What side effects might I experience?



Practical Considerations

- Can I start treatment right away?
- How far will I need to travel to receive treatment?
- How much logistical and caregiver support may be required?
- What is my preferred treatment schedule?



Personal Considerations

- What is most important to me about my treatment plan?
- What personal needs should I keep in mind when choosing a treatment?
- How much emotional support will I need from family and friends?

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

For Caregivers



Not an actual patient or caregiver.

The role of a caregiver is different for everyone, depending on your personal relationship and the needs of the person for whom you're caring. Below are some ways to help your loved one through their journey with FL.



Help with treatment

- Assisting with medications
- Helping to recognize side effects and discussing them with the healthcare team
- Keeping track of appointments
- Providing transportation



Communication and decision making

- Keeping other family members and friends informed
- Talking with the treatment team during visits and taking notes
- Helping to support discussions about starting, stopping, or continuing treatment



Emotional support

- Encouraging your loved one to share feelings, and supporting their efforts to share
- Letting them know you're available, but not pressing issues
- Remembering that people communicate in different ways

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use



We're Here to Support You During Treatment With MONJUVI

At IncyteCARES for MONJUVI, our mission is to help eligible patients get started with their medicine and to provide information and as-needed support throughout their treatment.

For Enrolled Patients, Our Team Will:

- Call you to review your insurance coverage for MONJUVI
- Assess your eligibility for savings and financial assistance programs*
- Explain additional support and resources available during your treatment

For more information and resources, visit [IncyteCARES.com/MONJUVI](https://www.incytecares.com/MONJUVI).

*Terms and conditions apply. Program terms may change at any time.



[IncyteCARES for MONJUVI Flashcard](#)

(0.5 MB)

Provides information about insurance, education, and support for patients.



Questions?

Call IncyteCARES for MONJUVI at
1-855-452-5234,
Monday through Friday, 8 AM–8 PM ET

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use

What's the next step on your mission?

MONJUVI may be the right choice if you want to:

- Consider an alternative treatment to chemotherapy that targets your cancer directly
- Maintain care with your existing healthcare team
- Receive outpatient treatment in a nearby clinic or infusion center and begin treatment as soon as you're ready.

For more information about MONJUVI or additional resources, visit MONJUVI.com/FL

Not an actual patient.



MONJUVI and the MONJUVI logo are registered trademarks of Incyte.
Incyte and the Incyte logo are registered trademarks of Incyte.
All other trademarks are the property of their respective owners.
© 2025, Incyte. MAT-MON-00563 07/25

Please see the full [Prescribing Information](#), including Patient Information, for more information about MONJUVI.

MONJUVI[®]
tafasitamab-cxix | 200mg
for injection, for intravenous use